A sleep aid is useful only when it matches the reason sleep is difficult. A structured insomnia treatment, a prescription medicine, an over-the-counter antihistamine, melatonin, an herbal supplement, a medical device, and an eye mask may all be described as sleep aids. They do different jobs, have different evidence, and are regulated differently.
For adults with chronic insomnia, cognitive behavioral therapy for insomnia, or CBT-I, is the best-supported first-line treatment. A prescription medicine may be considered through shared decision-making, but simply causing drowsiness does not make a product an effective or appropriate insomnia treatment 12.
This guide compares the categories. For ingredient-level evidence and product checks, use the focused guides to natural sleep aids, over-the-counter sleep aids, and sleep medication side effects. Decisions for a child belong in the separate sleep aids for kids guide and with the child's healthcare professional.
Start with the sleep problem
A reader asking for something to “help me sleep” may have one of several different problems:
- Not enough sleep opportunity: Work, caregiving, school, travel, or late activities leave too little time for sleep. A sedative cannot create missing time.
- Chronic insomnia: Difficulty falling asleep, staying asleep, or returning to sleep persists despite adequate opportunity and causes daytime consequences. When it occurs at least three times a week for more than three months and is not better explained by another cause, it can meet the pattern for chronic insomnia disorder 1.
- Circadian mistiming: Sleep may be normal on a later or earlier schedule but difficult at the time a person is required to sleep. Treatment is based on timing, not simply sedation.
- Symptoms that interrupt sleep: Pain, reflux, hot flashes, nocturia, breathing problems, an urge to move the legs, nightmares, or medication effects need cause-specific care.
- Excessive sleepiness: Unintended dozing or overwhelming sleepiness can reflect insufficient sleep, sleep apnea, narcolepsy, a medicine, or another condition. Making the person more sedated is not an assessment.
- An environmental obstacle: Light, noise, heat, cold, or a physically uncomfortable setup may respond to a practical comfort change without requiring a medical treatment.
This distinction is the first safety check. A product trial for occasional difficulty does not rule out a disorder, and a product studied for insomnia should not be assumed to treat sleep apnea or a circadian problem.
Sleep aid categories at a glance
| Category | When it may fit | Main evidence and safety boundary |
|---|---|---|
| CBT-I and related behavioral treatment | Chronic insomnia in adults | CBT-I is a multicomponent clinical treatment and is strongly recommended. General sleep-hygiene advice alone is not equivalent to CBT-I 21. |
| Prescription insomnia medicine | A defined sleep-onset or sleep-maintenance problem after individual assessment | Benefits and harms are drug-specific. Selection requires the diagnosis, other medicines, health conditions, impairment risk, and treatment goal to be reviewed 1. |
| OTC sedating antihistamine | Label-directed relief of occasional sleeplessness in an eligible adult | Diphenhydramine and doxylamine cause drowsiness but are not recommended as routine chronic-insomnia treatment. Next-day and anticholinergic effects matter 31. |
| Melatonin | Selected timing-related situations, such as some circadian disorders or jet lag | Melatonin is a timing signal and a dietary supplement in the United States. Evidence does not support treating it as a routine chronic-insomnia medicine 41. |
| Other dietary supplements | A narrowly defined, ingredient-specific question after interaction and product review | Evidence for many marketed sleep ingredients is limited or inconsistent. FDA does not approve supplements for safety or effectiveness before sale 56. |
| Digital or medical device | A validated treatment delivered digitally, or a device intended for a diagnosed condition | Intended use and evidence belong to the exact device and population. A tracker or wellness app is not automatically a diagnostic or treatment device 7. |
| Comfort product | A specific environmental or physical barrier, such as light, noise, or ordinary discomfort | It may make the sleep setting easier to tolerate, but it does not become an insomnia or sleep-apnea treatment because it is marketed for “deep sleep.” |
The table is not a ladder from weakest to strongest. A comfort product can be the sensible answer to a bright room, while a prescription drug would be an unnecessary mismatch. For chronic insomnia, however, repeatedly moving through store-bought products can delay the treatment with the strongest evidence.
CBT-I is treatment, not a list of bedtime tips
CBT-I addresses the patterns that keep insomnia going. A complete course commonly combines stimulus control, a carefully managed sleep window, cognitive work, relaxation strategies, and education. It uses a sleep history and ongoing response rather than one universal bedtime routine.
The American Academy of Sleep Medicine gives multicomponent CBT-I a strong recommendation for adults with chronic insomnia. The 2025 VA/DoD guideline also gives CBT-I a strong recommendation and suggests it over medication as first-line treatment. Both distinguish CBT-I from sleep-hygiene education alone 21.
CBT-I can be delivered in person, remotely, or through a structured digital program. Access and the amount of professional support vary. A relaxation app, sleep podcast, meditation recording, or generic list of sleep tips may be useful for some people, but it is not automatically a complete CBT-I program.
Do not copy the sleep-window component from a generic schedule. It may need modification or closer supervision for bipolar disorder, seizure disorders, untreated severe sleepiness, fall risk, pregnancy or postpartum demands, safety-sensitive work, and other clinical circumstances.
Where medication fits with CBT-I
A 2026 AASM guideline examined starting CBT-I and medication together. It conditionally favored the combination over medication alone, but conditionally favored CBT-I alone over starting the combination. The certainty was low, and individual goals and access still matter 8.
That evidence does not say medication is never appropriate. It places medication within an individualized plan rather than treating it as the default or as a replacement for CBT-I. It also does not provide a reason to add, substitute, or discontinue a medicine without the prescriber.
Prescription medicines are selected one drug at a time
Prescription insomnia medicines include several distinct groups:
- nonbenzodiazepine receptor agonists, often called Z-drugs;
- dual orexin receptor antagonists;
- low-dose doxepin formulated for sleep-maintenance insomnia;
- the melatonin-receptor agonist ramelteon; and
- benzodiazepines and other sedating medicines used in selected circumstances.
The groups differ in which insomnia symptoms they target, how long their effects may last, interactions, controlled-substance status, dependence or withdrawal concerns, next-day effects, and risks for a particular patient. A sedating antidepressant or antipsychotic used off-label is not automatically safer because it is not branded as a sleeping pill.
The 2025 VA/DoD guideline conditionally suggests certain dual orexin receptor antagonists, low-dose doxepin, and Z-drugs when pharmacotherapy is offered for chronic insomnia. It conditionally suggests against benzodiazepines, diphenhydramine, trazodone, and antipsychotics for that purpose. These are clinical recommendations for a defined disorder, not instructions to change an existing treatment without reviewing why it was prescribed 1.
Risks depend on the exact medicine
Many prescription insomnia medicines can impair alertness, coordination, memory, or balance during the night or the next day. The likelihood and duration are not the same for every drug or formulation.
FDA requires a boxed warning for eszopiclone, zaleplon, and zolpidem because rare complex sleep behaviors, including sleepwalking, sleep driving, and other activities while not fully awake, have caused serious injury and death. A person who has such an episode should follow the FDA warning and contact the prescriber immediately rather than taking another dose without review 9.
Benzodiazepines have separate boxed-warning concerns involving misuse, addiction, physical dependence, and dangerous withdrawal. Abrupt discontinuation or a rapid reduction can cause life-threatening reactions, including seizures 10. Other medicines have different label warnings. Do not increase, combine, taper, stop, or substitute a prescription sleep medicine based on a category comparison. The prescriber and pharmacist need the exact generic drug, formulation, current use, other substances, and medical history.
OTC antihistamines cause drowsiness, not a complete insomnia treatment
Most U.S. OTC drugs sold specifically as nighttime sleep aids use diphenhydramine or doxylamine. They are first-generation antihistamines. Their Drug Facts labels are directed at occasional sleeplessness, not ongoing treatment of chronic insomnia 3.
The distinction between an OTC drug and a dietary supplement is important. An OTC drug has a Drug Facts panel with an active ingredient, purpose, warnings, and directions. Melatonin and most herbal products use a Supplement Facts panel and follow a different regulatory framework.
Sedating antihistamines can cause next-day grogginess, slower reactions, dizziness, dry mouth, constipation, blurred vision, confusion, and difficulty urinating. Tolerance to the sedating effect can also make regular use less useful. The 2023 American Geriatrics Society Beers Criteria recommends avoiding oral diphenhydramine and doxylamine in most older adults because their anticholinergic burden raises concern for confusion, falls, delirium, and other adverse effects 11.
Brand families can hide duplicate ingredients. A sleep product, allergy medicine, and “PM” pain or cold product may contain the same antihistamine. Read every active ingredient and do not use a multi-symptom product solely for sedation. The detailed OTC sleep-aid guide explains Drug Facts labels, combination products, and next-day safety.
Melatonin is not a gentler version of an antihistamine
Melatonin helps signal biological night. That gives it a plausible and evidence-supported role in selected timing problems, including some cases of delayed sleep-wake phase disorder and jet lag. The relevant timing depends on the actual circadian problem, so taking it whenever sleep is difficult is not the same intervention 4.
For chronic insomnia in adults, current guidance does not support routine melatonin use. The 2025 VA/DoD guideline suggests against it for chronic insomnia, and NCCIH notes that major practice guidelines have found the efficacy and safety evidence inadequate for that use 14.
Melatonin sold in the United States is a dietary supplement. Product content may differ from the label, long-term safety remains uncertain, and interactions or health conditions may change the risk. NCCIH specifically identifies epilepsy and blood-thinner use as situations requiring medical supervision and notes insufficient safety evidence during pregnancy and breastfeeding 4.
No universal amount, clock time, or treatment length fits every sleep complaint. Use a diagnosis-specific plan rather than escalating the amount because a first attempt did not cause sedation.
Other supplements need ingredient-level evidence
Magnesium, valerian, chamomile, passionflower, lavender, glycine, tart cherry, cannabidiol, and multi-ingredient blends are not one treatment class. A trial of one extract in one population does not validate a tea, gummy, oil, powder, or blend with a different composition.
The evidence for many complementary sleep products is limited, inconsistent, or specific to a small study and a particular formulation. The 2025 VA/DoD guideline suggests against several commonly marketed botanicals and melatonin for chronic insomnia, finds insufficient evidence to recommend for or against magnesium, and recommends against kava. Those conclusions apply to chronic insomnia, not every possible traditional or dietary use 16.
FDA does not approve dietary supplements for safety or effectiveness, or approve their labeling, before they reach the market. Supplements can interact with medicines, affect laboratory tests or surgery, duplicate ingredients, and cause adverse effects. “Natural,” a higher amount, or a long ingredient list does not establish benefit or safety 5.
If a supplement is being considered, first define one target outcome and review the exact label with a pharmacist or clinician. The natural sleep-aids guide covers the evidence and safety boundaries for individual ingredients. This broad comparison is not a basis for choosing a dose or combining products.
Devices range from treatment delivery to simple tracking
A device or app can serve several very different purposes:
- a structured digital program can deliver CBT-I;
- a light device can be part of a timed circadian treatment;
- positive airway pressure or an oral appliance can treat diagnosed sleep apnea;
- a wearable can estimate sleep-wake patterns or flag a possible concern; and
- sound, cooling, vibration, or stimulation products may be marketed for relaxation or sleep.
Evidence and regulatory status do not transfer between those purposes. FDA clearance for one intended use, device version, or population does not validate every claim on a product page. Check the exact intended use and whether the product is prescription, over the counter, or a general-wellness product 7.
The AASM states that consumer sleep technology should be rigorously tested and appropriately cleared if it is intended to diagnose or treat a sleep disorder. A wearable score or app estimate is not a substitute for evaluation when symptoms persist or daytime sleepiness is significant 7.
Do not start self-directed bright-light treatment, airway therapy, electrical stimulation, or another disorder-specific device because a consumer tracker suggests a diagnosis. Use a disorder-specific device only for its intended purpose and with the evaluation, instructions, and follow-up that purpose requires.
Comfort products solve comfort problems
Eye masks, curtains, earplugs, sound machines, fans, bedding, pillows, and mattresses can be reasonable when they address a specific barrier. The test is practical: does the product reduce the light, noise, temperature discomfort, or pressure problem that is keeping this person awake?
A comfort product does not need to alter sleep stages to be useful. It also should not be credited with treating chronic insomnia, sleep apnea, pain disease, or anxiety without evidence for that exact claim. Marketing phrases such as “deep sleep,” “clinically inspired,” “neuroscience,” and “recovery” do not identify a studied medical outcome.
Match the product to the household. Earplugs or loud masking sound may be unsuitable when someone needs to hear a child, an alarm, or an emergency signal. A warming, cooling, powered, or weighted product needs its own instructions, recall check, electrical safety, mobility considerations, and condition-specific restrictions. If a product creates pain, numbness, overheating, breathing discomfort, dizziness, or anxiety, stop using it and address the actual problem.
A practical decision path
1. Describe the pattern
Note whether the problem is falling asleep, staying asleep, waking too early, sleeping at the wrong clock time, or feeling sleepy despite enough opportunity. Record when it began, how often it occurs, and what happens during the day.
2. Look for a cause that a sleep aid would miss
Loud snoring, gasping, breathing pauses, an urge to move the legs, dream enactment, pain, reflux, hot flashes, nocturia, panic, depression, mania, medication changes, and substance use can point to different care. A stronger sedative is not a universal answer.
3. Identify the category and regulatory status
Determine whether the option is behavioral treatment, a prescription drug, an OTC drug, a dietary supplement, a medical device, a general-wellness app, or a comfort product. Read the active ingredient or intended use rather than relying on the brand name.
4. Match evidence to the same problem
Ask whether the evidence studied occasional sleeplessness, chronic insomnia, jet lag, a circadian disorder, sleep apnea, or another condition. Check whether the same formulation, device, population, and outcome were tested.
5. Review the whole safety context
Include prescriptions, OTC drugs, supplements, alcohol, cannabis, health conditions, pregnancy or breastfeeding, falls, breathing conditions, and the need to drive or respond overnight. A pharmacist can identify duplicate ingredients and interactions.
6. Decide how success and harm will be judged
A useful plan has a defined target, such as a meaningful change in sleep onset, nighttime wakefulness, or next-day function. It also has a review point and a plan for side effects or lack of benefit. Those details should come from the prescriber, treatment program, or product label, not an improvised escalation.
People who need a narrower safety decision
Children and teenagers: Do not adapt an adult product, dose, or treatment plan. Pediatric sleep problems and melatonin decisions require age-specific assessment. Store every drug and supplement, including gummies, out of children's sight and reach; CDC surveillance estimated about 11,000 emergency department visits for unsupervised melatonin ingestion among U.S. children age 5 and younger during 2019 through 2022 12.
Pregnancy and breastfeeding: Ask the obstetric clinician and pharmacist before using a sleep drug, melatonin, an herb, CBD, or another supplement. Risk depends on the exact substance, timing in pregnancy, reason for treatment, and alternatives.
Older adults: Falls, confusion, slower drug clearance, kidney or liver function, and the combined burden of sedating or anticholinergic medicines can change the balance. OTC access does not remove that need for review 11.
Breathing, neurologic, liver, or kidney conditions: Sleep apnea, chronic lung disease, neuromuscular weakness, epilepsy, cognitive impairment, and reduced drug clearance can make a sedating product or a self-directed behavioral plan unsuitable.
Safety-sensitive responsibilities: Driving, operating machinery, working at height, responding to emergencies, and providing overnight care require reliable alertness. Do not drive or perform a safety-critical task while sleepy or impaired.
When to seek care
Arrange an assessment when insomnia persists, causes daytime impairment, or leads to repeated product use. Seek evaluation sooner for loud snoring, gasping, witnessed breathing pauses, severe daytime sleepiness, unexpected sleep episodes, an urge to move the legs, unusual nighttime behavior, a major mood change, or a sudden change from the person's usual sleep.
Contact the prescriber promptly after a possible complex sleep behavior, major next-day impairment, fall, confusion, hallucination, or other concerning medication effect. Do not make an unsupervised medication change while waiting for routine advice.
Seek emergency help for slow or difficult breathing, blue or gray color, inability to wake normally, collapse, seizure, severe allergic swelling, suspected overdose, a serious injury during nighttime behavior, or immediate risk of self-harm or harm to someone else.
The bottom line
There is no single best sleep aid. The right category depends on whether the problem is chronic insomnia, circadian mistiming, occasional sleeplessness, another disorder, or an uncomfortable sleep setting.
For chronic insomnia in adults, start with access to CBT-I rather than rotating through products. Prescription medicines require an individual benefit-and-risk decision. OTC antihistamines are limited to label-directed occasional use, melatonin is mainly a timing tool, and other supplements need ingredient-specific scrutiny. Devices must be judged by their exact intended use, while comfort products should be expected to improve comfort rather than treat a disorder.
Define the problem before choosing the aid, protect next-day alertness, and involve a clinician or pharmacist before combining or changing sedating products.
